الوهن العضلي الوبائي المعمم إيجابي AChR-Ab+: الخطوة التالية عندما لا يحقق ريتوكسيماب حالة التجلي الأدنى

References

DOI: 10.1212/WNL.0000000000011124

• Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG.
• Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals.
• In a phase II crossover RCT of 14 patients with refractory generalized AChR-Ab+ MG, at the end of the first treatment period, 6/7 (86%) of eculizumab-treated patients achieved the primary end point of a 2-point reduction in the QMG score, compared to 57% with placebo.
• In addition, 56% (65/116) of patients achieved MM status or pharmacologic remission.